clinical trial · NCT01106014
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
Actelion·phase3·completed·n = 1,156
Pulmonary Arterial HypertensionSelexipagPlacebo
brief summary
The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.
started
Dec 1, 2009
primary completion
Apr 1, 2014
completion
Oct 1, 2014
last updated
Oct 27, 2025
official title
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol